William Polonsky, PhD, CDE, explains where more benefits lie in T2D patients using the monitoring devices.
Continuous Glucose Monitoring (CGM) devices are not just for Type 1 diabetes (T1D) patients.
In fact, William Polonsky, PhD, CDE, would say Type 2 diabetes (T2D) patients receive more benefit from CGM than T1 patients do.
Polonsky, president of the Behavioral Diabetes Institute and an associate clinical professor at the University of California, San Diego, discussed recent research he led at the American Diabetes Association 77th Scientific Sessions in San Diego.
From what he learned in the study of GCM devices for T2D patients, the monitoring method goes appeciated.
"There were very, very high levels of treatment satisfaction — in fact, higher than any study I'm aware of," Polonsky said.
The T2D patients report more benefits to their own diabetes monitoring with newfound advantages in learning how lifestyle actions and decisions affect blood sugar, Polonsky said. Such information generally goes by unknown by the T2D patient group, and Polonsky hoped the study catches the ear of doctors.
"I hope this is really striking to healtchare providers as they're maybe reticent about the use of CGM data for Type 2's," Polonsky said. "At least from the point of personal treatment satisfaction, there's a huge amount of enthusiasm."